Abstract:Introduction: Glaucoma-related dry eye disease (DED) is often underestimated, but it is an important comorbidity affecting 40% to 59% of glaucoma patients. It may be an exacerbation of a pre-existing condition or a novel disease starting after the initiation of topical medication. The cumulative effect of medication, preservatives and excipients leads to an alteration in tear film composition and ocular surface stability. The main purpose of this investigation was to study a group of Portuguese glaucoma patients regarding the presence of DED symptoms and correlate the severity of the symptoms with the usage of different types of glaucoma topical medications. Materials and methods: This is a cross-sectional observational study of patients diagnosed with primary and secondary open-angle glaucoma. The questionnaire Standardized Patient Evaluation of Eye Dryness (SPEED) translated to Portuguese (SPEED-Vp) was taken by patients followed in the Glaucoma Department of Unidade Local de Saúde Entre Douro e Vouga, Santa Maria da Feira, Portugal. Data was collected regarding their age, gender, type of topical medication in use as well as frequency and duration of usage. A statistical analysis was performed. Results: A total of 75 patients answered the SPEED-Vp questionnaire. The mean age was 72 ± 7 years old. Fifty-two percent (n=39) were male, and 48% (n=36) were female patients. About 49.33% (n=37) had been on intraocular pressure (IOP)-lowering eyedrops for more than five years. About 61.43% (n=43) of patients used IOP-lowering eyedrops with preservatives. Most of the patients used prostaglandin analogs (75.71%, n=53) and beta-blockers (72.86%, n=51). SPEED score average was 2.75. About 25.33% (n=19) had no DED symptoms, 58.67% (n=44) had mild symptoms, 8% (n=6) had moderate symptoms and 8% (n=6) had severe symptoms. No statistically significant correlation was found between SPEED score and age, gender, number of eyedrop containers, number of active principles, application frequency, presence of preservatives, number of eyedrop containers with preservatives, duration of eyedrops usage or any of the medication groups. Conclusion: Although a high percentage of patients were on eyedrops with preservatives, this low rate of symptoms might be because patients tended to devalue these symptoms; were already on treatment with artificial tears; or have an underestimation of the sensation of dry eye due to decreased neuronal corneal nerve responses and density. These results were surprisingly positive. This might also be the result of the healthcare provider's sensibilization to this issue (early diagnosis, early prescription of artificial tears and change from preservative to preservative-free medication).

"Dirty Dry Eye"– A waste volume analysis from topical therapy in keratoconjunctivitis sicca

Patient-reported burden and overall impact of dry eye disease across eight European countries: a cross-sectional web-based survey

Achieving net-zero in the dry eye disease care pathway

The carbon footprint and wastage of intravitreal injections

Estimated Annual Economic Burden of Dry Eye Disease Based on a Multi-Center Analysis in China: A Retrospective Study

Expert opinion in the management of aqueous Deficient Dry Eye Disease (DED)

Influence of Environmental Factors with Clinical Signs and Symptoms in the Management of Dry Eye Disease

Dry Eye and Clinical Disease of Tear Film, Diagnosis and Management

Patient-Reported Dry Eye Treatment and Burden of Care

Real Life Impact of Dry Eye Disease

One Soul and Several Faces of Evaporative Dry Eye Disease

Historical Profiling of Dry Eye Patients - Potential Trigger Factors and Comorbidities

THE ANALYSIS STUDY OF INTERVENTIONS FOR DRY EYES: A COMPREHENSIVE SYSTEMATIC REVIEW

Overview of 37 Tear Substitutes in Europe Based on Various Physicochemical Parameters

Dry eye: prevalence, utilization, and economic implications

Prevailing practices for the management of dry eye disease in India: A questionnaire based survey 2023

Comprehensive dry eye therapy: overcoming ocular surface barrier and combating inflammation, oxidation, and mitochondrial damage

Intravitreale Injektionen: Nachhaltigkeit durch Reduktion von KlinikabfallIntravitreal Injections: Improving Sustainability by Reducing Clinical Waste

Managing Dry Eye Disease with Novel Medications: Mechanism, Study Validity, Safety, Efficacy, and Practical Application

Real-world insights and outcomes related to ciclosporin A 0.1% cationic emulsion for the long-term treatment of dry eye disease in Germany: Country-level sub-analysis of the PERSPECTIVE study

Dry Eye Disease Symptoms Among Glaucoma Patients at a Portuguese Hospital